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Abstract
Background: Among Influenza neuraminidase inhibitors (NAIs), oseltamivir corresponds to the most widely used
agent to treat influenza disease. However since 2001, several cases of resistance to NAIs have been reported for
circulating seasonal A(H1N1) Influenza viruses. A direct resistance mechanism may be invoked, involving critical
mutations in the viral NA gene that prevent the drug binding to its target. Same phenomenon is reported for
adamantanes drugs and mutations in the M2 channel protein gene of Influenza viruses.
Methods: Reverse-Transcription/Restriction Fragment Length Polymorphism (RT-PCR/RFLP) method, phenotypic
testing for oseltamivir resistance, and sequencing of NA, HA and M2 genes were used in this study. Phylogenetic
analyses were performed using BioEdit and Mega 5 softwares for alignment of sequences and phylogenetic trees
building respectively.
Results: Using a simple RT-PCR/RFLP method, we found that the 86 seasonal A(H1N1) isolates from 2008 bear the
oseltamivir resistance-associated mutation (H274Y) in the NA gene. In contrast all isolates isolated in Senegal in
2007 were sensitive to oseltamivir. These results were first confirmed by finding high IC50 values using a
phenotypic testing for oseltamivir resistance, and secondly by sequencing the whole NA gene. Regarding M2 gene,
no mutation associated to adamantanes resistance was characterized of the isolates.
Conclusions: The present work provides evidence of circulation of drug-resistant seasonal A(H1N1) viruses during
the 2008 influenza season (July to September) in Senegal. The results are in favor of multiple introductions of
oseltamivir resistant viruses (ORV) A(H1N1) in Senegal.
Phylogenetic analyses of isolates with complete sequences of N1 and HA1 genes showed that they belong to clade
2B and suggest sequential introductions in Africa.
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Background
An important progress in the treatment of influenza
during the past decade has been the development of
potent, selective inhibitors of the viral neuraminidase
(NA) enzyme. This was especially achieved through the
structure-based design of carboxylic sialic acid analogues
interacting with the NA active site, a highly conserved site
in both influenza A and B viruses [1,2]. Among these NA
inhibitors (NAIs), oseltamivir corresponds to the most
widely used agent to treat influenza disease. However
since 2001, sporadic cases of resistance to NAIs have been
reported [3,4]. A direct resistance mechanism may be
invoked, involving some mutations in the viral NA gene
that prevent the drug binding to its target [5]. The relation
between oseltamivir resistance and histidine-to-tyrosine
mutation at the position 274 (275 in N1 numbering
system) was clearly established [6].
The major event of the 2007-2008 influenza season in
Europe was the emergence of oseltamivir-resistant sea-
sonal A(H1N1) viruses. Indeed, by the end of January
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2008, the emergence of influenza A(H1N1) oseltamivir-
resistant viruses (ORV) was first reported in Norway
[7,8], and rapidly in many other European countries
[9,10]. The overall frequency of oseltamivir resistance in
A(H1N1) viruses from Europe was 25%, with variation
between countries; Norway detecting the highest propor-
tion (67%), and others have detected proportions as low
as 2%, e.g in Spain [9]. Following the emergence of this
resistant strain in Europe, these variants were also
reported in the southern hemisphere [11]. With regard to
Africa, the first surveillance data on oseltamivir resistance
came from South Africa and showed that all viruses
isolated in 2008 were resistant to oseltamivir, on the basis
of ARMS PCR results [12]. Given that the predominant
subtype of influenza virus circulating in Senegal during
the 2008 season (from July to October) was seasonal A
(H1N1), we used these isolates to test whether the spread
of oseltamivir-resistant variants may have reached coun-
tries in the inter-tropical areas of Africa.
Two adamantane derivatives, amantadine and riman-
tadine namely, are also used as antiviral drugs for prophy-
laxis and treatment of influenza. These drugs bind to and
block the function of the influenza A virus M2 ion chan-
nel protein, preventing virus replication within the
infected cell [13]. So resistance to adamantanes can emerge
during treatment. A single point mutation in the sequence
coding for the amino acid at position 26, 27, 30, 31, or 34
of the M2 protein confers resistance to the adamantanes
[14,15]. In this study, in addition to oseltamivir resistance,
our aim is also to look for these genetic markers for
adamantane resistance by sequencing the critical region
of the M2 gene harboring these different amino acid
positions.
It is worth noting that no influenza antiviral agents,
including oseltamivir, amantadine or rimantadine, were
used in Senegal.
Methods
Specimens were collected from subjects with influenza-
like illnesses as part of the sentinel surveillance system
for Influenza-like Illness (ILI) conducted in Dakar since
1996 and as requested by the Ministry of Health in order
to decipher the etiology of febrile illnesses in children
seeking care in primary healthcare centers in Dakar.
An ILI case was identified as an outpatient presenting
with sudden onset of fever (≥38°C) and cough or sore
throat, accompanied or not by myalgia, prostration, head-
ache or malaise, with the onset of symptoms occurring
within the previous 3 days. A standardized questionnaire
was used to collect demographic and clinical information
from the enrolled patients. Throat and/or nasopharyngeal
swabs were taken from patients within 48–72 hours from
onset of symptoms and then tested for virus isolation and/
or molecular detection with standard protocols validated
by WHO. When both throat and nasal swabs were avail-
able, the two samples were collected in the same tube to
increase sensitivity of testing. Aliquots of samples were
also stored at -80°C for further analysis.
For virus isolation, the clinical materials obtained from
patients were inoculated on Madin Darby Canine Kidney
(MDCK) cell lines as described previously [16]. Tissue cul-
ture fluid was harvested after observing inoculated MDCK
cell line for cytopathic effect. Hemagglutination and
Hemagglutination Inhibition (HAI) tests were performed
(detection and typing of viruses) using specific antisera, as
recommended by WHO standard protocols [17].
For molecular characterizations, ribonucleic acid (RNA)
extraction was performed from 200 μl of each sample
using the QIAamp Viral RNA kit (QIAGEN, Valencia,
CA, USA) according to the manufacturer’s instructions.
Each RNA sample was eluted with 50 μl of nuclease-free
water.
We used an RT-PCR/RFLP technical [18] to discrimin-
ate between oseltamivir-sensitive and oseltamivir-resistant
influenza A(H1N1) isolates. RT-PCR primers target a 183-
bp region of the NA gene, encompassing the codon prone
to H274Y mutation (N1-770Fw: AGA TCG AAA AGG
GGA AGG TTA CTA, and N1-881Rv: TCC CTG CAT
ACA CAC ATC ACT). Briefly, 6 μl of each RT-PCR pro-
duct were digested with BspHI (New England BiolabsW) in
a final volume of 20 μl, the restriction site for this enzyme
(TCATGA/AGTACT palindrome) covering the codon 274
(H: CAT/Y: TAT). Thus, BspHI should cut only amplicons
without mutation, i.e. amplicons from oseltamivir-sensitive
A(H1N1) viruses (predicted size of the major digest pro-
duct: 147 bp). Digested and undigested amplicons were
co-electrophoresed on 2% agarose with appropriated mo-
lecular weight markers (100 bp ladder, New England
BiolabsW). Oseltamivir-sensitive isolates from the 2007 In-
fluenza season served as positive controls for BspHI diges-
tion. Gels were stained with ethidium bromide (0.5 μg/ml).
The matrix M2 gene was amplified and sequenced in
order to look for mutations conferring resistance to
adamantanes.
Selected viruses were phenotypically (resistance to
NAI), antigenically, and genetically characterized by the
WHO Collaborating Centre for Influenza at the National
Institute for Medical Research (NIMR) in London, UK.
The influenza virus neuraminidase (NA) activity of the
isolates and sensitivity to neuraminidase inhibitors (NI)
was measured by an enzyme assay using a fluorogenic
substrate i.e MUNANA (2’ 20-(4-Methylumbelliferyl)-α-D-
N-acetylneuraminic acid sodium salt hydrate) with known
NA inhibitor-resistant viruses as controls. HA and NA
genes were sequenced using ABI Prism BigDye terminator
cycle sequencing kits and an ABI-3730XL DNA analyser.
Phylogenetic analysis of the neuraminidase whole gene se-
quence (1400 bp) and the haemagglutinin HA1 genes
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(1200 first bp) of H1N1 viruses were performed using
MEGA version 5 [19] for constructing Maximum Likeli-
hood Tree using the Tamura-nei evolutionary model.
Alignments of sequences were performed using the
BioEdit Sequence alignment Editor [20].
The surveillance protocol was approved as less than
minimal risk research by the Senegalese National Ethical
Committee of the Ministry of Health, and written con-
sent forms were not required. Throughout the study, the
database was shared with the Epidemiology Department
at the Senegalese Ministry of Health and Prevention for
appropriate public health actions.
Results
A total of 86 H1N1 viruses were isolated from July 2008
(week 28) to September 2008 (week 38). The median age
of patients tested positive for viral isolation was 5 years
(range: from 2 months to 48 years), 66% of these
patients being young children (no more than 2 years)
and most of them (74%) living in the suburbs of Dakar.
The data showed that PCR products from all 86 isolates
of the 2008 season are not digested by the restriction
enzyme BspHI in contrast to the 2007 isolates (Figure 1).
This suggests a high frequency of the H274Y mutation
in the N1 gene and therefore a potential resistance to
oseltamivir of the studied viruses. The emergence of
oseltamivir-resistant viruses in 2008 was confirmed by the
finding of a high IC50 mean value (859.3 nM) compared to
the one obtained for 2007 viruses (between 1 and 2 nM)
(Table 1). In 2007, all the 27 A/(H1N1) strains sent to the
WHOCollaborating Centre for Influenza in NIMR, London,
were sensitive to Oseltamivir and didn’t harbor the H274Y
mutation.
Ten (10) isolates were tested for resistance to adaman-
tanes and oseltamivir through sequencing of the matrix
M2 gene and the N1 portion that recover the H275Y
mutation. None of the five mutations conferring resist-
ance to adamantanes [21] were detected in contrast all
isolates harbored the H275Y mutation conferring oselta-
mivir resistance.
The N1 gene of the four (4) isolates (GISAID identifica-
tion numbers: A/Dakar/03/2008/EPI_ISL_65453, A/Dakar/
06/2008/EPI_ISL_65454, A/Dakar/09/2008/EPI_ISL_65455
and A/Dakar/14/2008/EPI_ISL_65456) for which sequen-
cing were done in a WHO Collaborative Center (NIMR,
London, UK) were then analyzed along with published N1
sequences (Figure 2). As expected, all Dakar isolates were
in a sub-clade carrying the H275Y mutation.
To evaluate the genetic heterogeneity of Dakar
isolates, we undertook a phylogenetic analysis based
on the HA1 portion of the hemagglutinin (HA) gene.
HA1 sequencing was performed in five randomly








EPI_ISL_18609) were sequenced in NIMR, WHO CC,
London and included in this study. No systematic geo-
graphic clustering of the viruses collected from different
continents (Africa, Europe and North America) is evident
Figure 1 RT-PCR/RFLP analysis of the NA gene of seasonal A
(H1N1) influenza viruses digestion with BspHI enzyme of DNA
amplicons obtained by RT-PCR targeting the neuraminidase
gene of influenza A(H1N1) isolates and covering the mutation
site conferring oseltamivir resistance. Tracks A to D: A(H1N1)
viruses isolated in 2008; Tracks F to I: A(H1N1) viruses isolated in
2007; Tracks A, C, F, H: amplicons digested with BspHI, Tracks B, D, G,
I: undigested PCR amplicons. Track E: 100-base pair marker (New
England BioLabs).
Table 1 Phenotypes of seasonal influenza A(H1N1)
viruses isolated in Dakar, Senegal, in 2008












* S = Sensitive; R = Resistant.
Results of testing sensitivity to oseltamivir.
Phenotypic resistance to oseltamivir for seasonal influenza A(H1N1) viruses
isolated in 2008 is compared with isolates obtained in 2007, in Dakar, Senegal.
The mean value of the Inhibition Concentration 50 for 2008 isolates is
859.3nM (range from 430.5 to 1115.3).
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as shown in the phylogenetic tree (Figure 3). So all 2008
viruses isolated in Dakar, Senegal, are distributed into a
well-distinct group. These isolates cluster in a diverging
sub-clade, characterized by two characteristic mutations in
the HA1 segment compared to the other isolates (S141N
and G185A). In this sub-clade are also represented isolates
from Europe, Asia, North America and others African
countries. The remaining isolate from Dakar (A/Dakar/18/
07, isolated in 2007) belong to a different group which
comprise the A/Brisbane/59/2007 vaccine virus. These
results are strongly in favor of multiple introductions of A
(H1N1) ORV in Senegal in 2008.
Discussion
In this paper sequencing of Influenza NA genes has
validated utilization of RT-PCR-RFLP method for direct
detection of oseltamivir-resistant influenza viruses, with
a 100% concordance between the two methods. This
method will then be a very useful tool for laboratories
without direct access to sequencing facilities, as many la-
boratories in poor resource settings, including Africa.
The present work also provides the first evidence of cir-
culation of drug-resistant A(H1N1) viruses during the
2008 influenza season (July to September) in Senegal
after years of flu monitoring [22], as previously reported
for South Africa [12]. These results are in favor of mul-
tiple introductions of oseltamivir resistant viruses (ORV)
A(H1N1) in Senegal, rather than a re-emergence of pre-
viously circulating viruses that developed resistance to
oseltamivir. Indeed all influenza A(H1N1) viruses in
2007 in Senegal were sensitive to Oseltamivir and this
drug has not been used in Senegal to treat patients
infected by influenza virus. Even if some studies
supported that oseltamivir resistance is low in patients
Figure 2 Phylogeny of of the NA gene of seasonal A(H1N1) influenza viruses. Phylogenetic analysis of the neuraminadase gene sequences
of H1N1 viruses, using MEGA version 5 for constructing Maximum Likelihood Tree using the Tamura-nei evolutionary model. The prototype
reference strains for each clade are colored in purple, the contemporary vaccine virus recommended for inclusion of the trivalent influenza
vaccine for the 2008/2009 Northern Hemisphere winter is shown in blue ; Viruses from Dakar, Senegal, are shown in red. The group indicated by
the asterix carries the H275Y amino acid substitution.
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treated with oseltamivir [23], two previous studies in
Japan revealed that oseltamivir resistance emerged in
18% and 16% of treated Japanese children with influenza
virus A(H3N2) and A(H1N1) infection respectively
[24,25]. Moreover, prescription data for NAI treatment
indicate that these drugs are not widely used in Europe
despite the high rate of spread in a short time [11]; by
contrast, in Japan just during the 2003–04 season, ≈6
million NAI treatment courses were prescribed [26].
The close relationships of the viruses isolated in Dakar
with those from Europe, North America, Asia and other
African countries, as shown by phylogenetic analyses, may
signal virus’ introduction(s) in Dakar from these areas. In-
deed the air traffic between Dakar and these countries is
quite dense. However, it is more probable that the spread
of oseltamivir-resistant influenza A(H1N1) viruses may
have followed a path from South Africa northwards to the
Sahelian regions of Africa. To substantiate this hypothesis,
the phylogenetic tree based on the HA1 gene (Figure 3)
show a genetic/antigenic drift (in comparison to the 2007
reference and vaccine strains) more marked for viruses
from West Africa (Ghana and from Senegal) than for
viruses from Southern and Central Africa. Strains isolated
in Senegal in 2008 are exclusively located in a group ex-
cluding viruses from South Africa and Cameroon. More-
over, it is well established that South Africa is the first
country in Africa that reported ORV cases [12], three
months before detection of such cases in Senegal. In
addition, RT-PCR/RFLP analysis of influenza A(H1N1)
viruses detected in Mauritania (located in the north of
Senegal) in December 2008 showed that they are resistant
to oseltamivir and closely related to viruses that have
Figure 3 Phylogeny of HA1 segment of the HA gene of seasonal A(H1N1) influenza viruses. Phylogenetic analysis of the neuraminadase
gene sequences of H1N1 viruses, using MEGA version 5 for constructing Maximum Likelihood Tree using the Tamura-nei evolutionary model. The
prototype reference strains for each clade are colored in purple, the contemporary vaccine virus recommended for inclusion of the trivalent
influenza vaccine for the 2008/2009 Northern Hemisphere winter is shown in blue ; Viruses from Dakar, Senegal, are shown in red.
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circulated in Senegal three to four months ago (data not
shown). Thus the South-to-North spread of drug-resistant
influenza viruses in Africa seems likely even if one cannot
exclude some direct seeding from other regions. Even
though analyses of influenza viruses bearing the H274Y
marker conferring resistance to oseltamivir provides some
clues, further studies are needed to decipher the complex
dynamics of Influenza in the African continent. Indeed,
(i) the lack of data on the month of isolation of some
strains included in the phylogenetic tree, and (ii) the in-
trinsic limitation of the surveillance systems to rapidly
detect introduction of influenza strains and discrimination
of infections acquired within or outside the country, can-
not allow proper tracking of the timeline of introduction
of these oseltamivir resistant viruses in each country. On
an another hand, even if the travel history of the enrolled
patients was not always known it is probable that
infections occurred within the country as the study popu-
lation is sedentary and the majority (66%) of enrolled
patients is children less than 2 years old.
Conclusions
The present study provides genetic evidence of circulation
of drug-resistant seasonal A(H1N1) viruses in Senegal du-
ring the 2008 influenza season (July to September). It
shows that RT-PCR-RFLP method, a simple, reliable and
cheap tool can be useful for low-resources’ laboratories to
detect circulation of oseltamivir-resistant A(H1N1) viruses.
Moreover, the results are in favor of multiple introductions
of oseltamivir resistant viruses (ORV) A(H1N1) in Senegal.
Phylogenetic analyses of these isolates with complete
sequences of N1 and HA1 genes from other continents
and areas in Africa showed that they belong to clade 2B
and suggest sequential introductions and internal dynamics
in Africa during the 2008-2009 Influenza season.
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